Novel Vaccine Delivery Devices Market, 2019-2030

Description Table of
Contents Companies Mentioned Methodology

“According to Experts, The Global Vaccines Market is Anticipated to Generate Revenues Worth USD 100 Billion by 2025”

FEATURED COMPANIES

3M
BioNTech
Genentech
Likang Life Sciences
Osaka University
Transgene
MORE

Overview

According to experts, the global vaccines market is anticipated to generate revenues worth USD 100 billion by 2025. Data presented by the WHO indicates that the current global vaccination coverage is nearly 85%; this is believed to be responsible for preventing close to three million deaths from diseases, such as diphtheria, tetanus, whooping cough and measles. Recent global immunization records indicate that more than 115 million children were immunized against diphtheria, tetanus and pertussis in 2018. Given the rate at which the global population is growing, the demand for vaccines is likely to increase significantly.

However, biopharmaceutical developers are plagued by concerns related to storage and handling of such preventive / therapeutic products. One commonly reported issue is related to vaccine administration. Despite the success of conventional delivery approaches, which rely on the intramuscular and subcutaneous routes of administration, the present scenario dictates that further improvements are required in order to deal with challenges related to large scale immunization initiatives. Some of the commonly reported disadvantages of the conventional (parenteral) mode of delivery include pain during administration, risk of cross contamination, needlestick injuries, and inaccurate dosing.

Of late, there has been an evident shift in interest to non-invasive immunization methods, which include oral, intranasal and transdermal modes of administration. Currently, many biopharmaceutical companies and clinical research institutes are engaged in the development of novel vaccine delivery systems, taking into consideration the specific requirements of large scale immunization initiatives. As a result, significant efforts have been put into the development of drug delivery technologies / devices, such as microneedle patches, electroporation-based needle free injection systems, jet injectors, inhalation-based delivery systems, biodegradable implants and certain novel types of oral delivery systems.

It is worth highlighting that most of the aforementioned systems are specifically being designed to facilitate pain-free administration of vaccines and allow self-administration. Vaccine developers are also attempting to devise ways to make such products more stable so as to eliminate the need for cold chain in transporting such products. Given the pace of innovation in this field, it is anticipated that the novel vaccine delivery devices market is likely to witness radical changes in the coming years.

Scope of the Report

The “Novel Vaccine Delivery Devices Market, 2019-2030” report features an extensive study of the current landscape and the likely future opportunities associated with novel vaccine delivery devices, over the next 10-12 years. Amongst other elements, the report includes:

A detailed assessment of the overall novel vaccine delivery devices market landscape, featuring an elaborate list of device developers and analysis based on a number of relevant parameters, such as year of establishment, company size, geographical location, type of device (autoinjectors, microneedle patches, jet injectors, dry powder inhalers, microinjectors, nasal delivery systems, pen injectors, biodegradable implants, electroporation-based needle free injection systems and novel oral delivery systems), route of administration (subcutaneous, transdermal, intramuscular, intradermal, inhalation, intranasal, and oral), drug delivery mechanism (mechanical, electrical and miscellaneous), nature of vaccine administration (invasive and non-invasive), speed of administration (fast, moderate and slow), self- administration potential, provisions for audio / visual feedback, device usability (disposable and reusable), type of needle (needleless, fixed needle, detachable needle, and hidden needle), and current development status of novel vaccine delivery systems (preclinical / discovery, clinical and marketed).
A detailed competitiveness analysis of novel vaccine delivery devices, taking into consideration the supplier power (based on the year of establishment of developer company) and key product specifications (such as route of administration, device usability, drug delivery mechanism, availability of needle safety system, speed of administration, self-administration potential, provisions for audio / visual feedback, nature of administration, cold chain requirement and current status of development).
An analysis evaluating the effectiveness of various vaccines delivery devices in order to compare their respective strengths and capabilities based on a variety of relevant parameters, such as type of active ingredient, dosage form, route of administration, target disease indication and target patient population.
A detailed list of marketed and pipeline vaccine candidates that are anticipated to be developed in combination with novel vaccine delivery devices in the near future, featuring analysis based on parameters, such as type of active ingredient, dosage form, route of administration, target disease indication and target patient population.
Elaborate profiles of prominent product developers engaged in this domain; each profile features a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and an informed future outlook.
An analysis of recent collaborations and partnership agreements inked in this domain since 2014, including details of deals that were / are focused on novel vaccine delivery devices. The partnerships captured in the report were analyzed on the basis of year of establishment, type of agreement, type of device, type of vaccine, type of active ingredient and target disease indication.
A discussion on important, industry-specific trends, key market drivers and challenges, under a comprehensive SWOT framework, featuring a qualitative Harvey ball analysis that highlights the relative impact of each SWOT parameter on the overall market.

One of the key objectives of the report was to estimate the existing market size and assess potential future growth opportunities for novel vaccine delivery devices. Based on various parameters, such as number of marketed / pipeline products, price of devices (for commercially available products only) and estimated annual adoption rate, we have developed an informed estimate on the likely evolution of the market over the period 2019-2030. In addition, we have provided the likely distribution of the current and forecasted opportunities across [A] type of device (electroporation-based needle free injection systems, oral delivery systems, nasal delivery systems, jet injectors, microneedle patches and microinjectors), [B] route of administration (oral, intramuscular, intranasal, intradermal and subcutaneous), [C] type of vaccine (Bivalent Oral Polio Vaccine, BCG Vaccine, DTP-HepB-Hib Vaccine, Pneumococcal Conjugate Vaccine, Influenza Vaccine, Measles Vaccine, Tetanus-Diphtheria Vaccine and Others) and [D] key geographical regions (North America, Europe, Asia and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

Michael Schrader, Chief Executive Officer and Founder, Vaxess Technologies
Mikael Ekstrom and Roger Lassing, Vice President, Business Development, Iconovo
Henry King, Market Intelligence and Business Development Manager, Innoture

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

3M
BioNTech
Genentech
Likang Life Sciences
Osaka University
Transgene
MORE

1. PREFACE

1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview
3.2. Vaccines
3.2.1. Classification of Vaccines
3.2.1.1. Live, Attenuated Vaccines
3.2.1.2. Inactivated Vaccines
3.2.1.3. Subunit Vaccines
3.2.1.4. Toxoid Vaccines
3.2.1.5. DNA Vaccines
3.2.2. Key Components of a Vaccine Formulation
3.2.3. Expression Systems Used for Vaccine Production
3.2.3.1. Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs)
3.2.3.2. Mammalian Expression Systems
3.2.3.3. Avian Expression Systems
3.2.3.4. Plant Expression Systems
3.2.3.5. Bacterial Expression Systems
3.2.3.6. Yeast Expression Systems
3.2.3.7. Insect Expression Systems
3.3. Vaccine Delivery
3.3.1. Intradermal Route
3.3.2. Subcutaneous Route
3.3.3. Intramuscular Route
3.3.4. Oral Route
3.3.5. Intranasal Route
3.3.6. Inhalation Route
3.4. Key Challenges Associated with Vaccine Delivery
3.5. Novel Approaches for Vaccine Delivery
3.5.1. Autoinjectors
3.5.2. Biodegradable Implants
3.5.3. Buccal / Sublingual Vaccine Delivery Systems
3.5.4. Electroporation-based Needle Free Injection Systems
3.5.5. Inhalation / Pulmonary Vaccine Delivery Systems
3.5.6. Jet Injectors
3.5.7. Microinjection System
3.5.8. Novel Orally Administrable Formulations
3.6. Future Perspectives

4. MARKET LANDSCAPE

4.1. Chapter Overview
4.2. Marketed Vaccines Landscape
4.3. Clinical-Stage Vaccines Landscape
4.4. Novel Vaccine Delivery Devices: Overall Market Landscape
4.4.1. Analysis by Type of Device
4.4.2. Analysis by Route of Administration
4.4.3. Analysis by Drug Delivery Mechanism
4.4.4. Analysis by Nature of Vaccine Administration
4.4.5. Analysis by Speed of Vaccine Administration
4.4.6. Analysis by Self-Administration Potential
4.4.7. Analysis by Availability of Audio / Visual Feedback
4.4.8. Analysis by Device Usability
4.4.9. Analysis by Type of Needle
4.4.10. Analysis by Stage of Development
4.5. Novel Vaccine Delivery Device Developers: Overall Market Landscape
4.5.1. Analysis by Type of Developer
4.5.2. Analysis by Year of Establishment
4.5.3. Analysis by Company Size
4.54. Analysis by Geographical Location

5. DEVICE COMPETITIVENESS ANALYSIS

5.1. Chapter overview
5.2. Assumptions and Methodology
5.3. Novel Vaccine Delivery Devices: Competitive Landscape
5.4. Concluding Remarks

6. TECHNOLOGY EFFECTIVENESS ANALYSIS

6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. Vaccine Delivery Devices: Technology Effectiveness Analysis
6.4.1. Devices for Marketed Vaccines
6.4.1.1. Analysis by Type of Active Ingredient
6.4.1.2. Analysis by Dosage Form
6.4.1.3. Analysis by Route of Administration
6.4.1.4. Analysis by Target Disease Indication
6.4.1.5. Analysis by Target Patient Population
6.4.2. Devices for Clinical-Stage Vaccines
6.4.2.1. Analysis by Type of Active Ingredient
6.4.2.2. Analysis by Dosage Form
6..2.3. Analysis by Route of Administration
6.4.2.4. Analysis by Target Disease Indication
6.4.2.5. Analysis by Target Patient Population

7. NOVEL VACCINE DELIVERY DEVICES: LIKELY VACCINE CANDIDATES

7.1. Chapter Overview
7.2. Marketed Vaccines
7.2.1. Electroporation-based Needle Free Injection Systems: Likely Vaccine Candidates
7.2.1.1. Most Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
7.2.1.2. Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
7.2.1.3. Less Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
7.2.1.4. Least Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
7.2.2. Jet Injectors: Likely Vaccine Candidates
7.2.2.1. Most Likely Candidates for Delivery via Jet Injectors
7.2.2.2. Likely Candidates for Delivery via Jet Injectors
7.2.2.3. Less Likely Candidates for Delivery via Jet Injectors
7.2.2.4. Least Likely Candidates for Delivery via Jet Injectors
7.2.3. Microneedle Patches: Likely Vaccine Candidates
7.2.3.1. Most Likely Candidates for Delivery via Microneedle Patches
7.2.3.2. Likely Candidates for Delivery via Microneedle Patches
7.2.3.3. Less Likely Candidates for Delivery via Microneedle Patches
7.2.3.4. Least Likely Candidates for Delivery via Microneedle Patches
7.2.4. Nasal Delivery Systems: Likely Vaccine Candidates
7.2.4.1. Most Likely Candidates for Delivery via Nasal Delivery Systems
7.2.4.2. Likely Candidates for Delivery via Nasal Delivery Systems
7.2.4.3. Less Likely Candidates for Delivery via Nasal Delivery Systems
7.2.4.4. Least Likely Candidates for Delivery via Nasal Delivery Systems
7.2.5. Oral Delivery Systems for Liquid Formulations: Likely Vaccine Candidates
7.2.5.1. Most Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
7.2.5.2. Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
7.2.5.3. Less Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
7.2.5.4. Least Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
7.2.6. Oral Delivery Systems for Solid Formulations: Likely Vaccine Candidates
7.2.6.1. Most Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
7.2.6.2. Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
7.2.6.3. Less Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
7.2.6.4. Least Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
7.2.7. Prefilled Syringes: Likely Vaccine Candidates
7.2.7.1. Most Likely Candidates for Delivery via Prefilled Syringes
7.2.7.2. Likely Candidates for Delivery via Prefilled Syringes
7.2.7.3. Less Likely Candidates for Delivery via Prefilled Syringes
7.2.7.4. Least Likely Candidates for Delivery via Prefilled Syringes
7.3. Clinical-Stage Vaccines
7.3.1. Electroporation-based Needle Free Injection Systems: Likely Vaccine Candidates
7.3.1.1. Most Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
7.3.1.2. Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
7.3.1.3. Less Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
7.3.1.4. Least Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
7.3.2. Jet Injectors: Likely Vaccine Candidates
7.3.2.1. Most Likely Candidates for Delivery via Jet Injectors
7.3.2.2. Likely Candidates for Delivery via Jet Injectors
7.3.2.3. Less Likely Candidates for Delivery via Jet Injectors
7.3.2.4. Least Likely Candidates for Delivery via Jet Injectors
7.3.3. Microneedle Patches: Likely Vaccine Candidates
7.3.3.1. Most Likely Candidates for Delivery via Microneedle Patches
7.3.3.2. Likely Candidates for Delivery via Microneedle Patches
7.3.3.3. Less Likely Candidates for Delivery via Microneedle Patches
7.3.3.4. Least Likely Candidates for Delivery via Microneedle Patches
7.3.4. Nasal Delivery Systems: Likely Vaccine Candidates
7.3.4.1. Most Likely Candidates for Delivery via Nasal Delivery Systems
7.3.4.2. Likely Candidates for Delivery via Nasal Delivery Systems
7.3.4.3. Less Likely Candidates for Delivery via Nasal Delivery Systems
7.3.4.4. Least Likely Candidates for Delivery via Nasal Delivery Systems
7.3.5. Oral Delivery Systems for Liquid Formulations: Likely Vaccine Candidates
7.3.5.1. Most Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
7.3.5.2. Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
7.3.5.3. Less Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
7.3.5.4. Least Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
7.3.6. Oral Delivery Systems for Solid Formulations: Likely Vaccine Candidates
7.3.6.1. Most Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
7.3.6.2. Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
7.3.6.3. Less Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
7.3.6.4. Least Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
7.3.7. Prefilled Syringes: Likely Vaccine Candidates
7.3.7.1. Most Likely Candidates for Delivery via Prefilled Syringes
7.3.7.2. Likely Candidates for Delivery via Prefilled Syringes
7.3.7.3. Less Likely Candidates for Delivery via Prefilled Syringes
7.3.7.4. Least Likely Candidates for Delivery via Prefilled Syringes

8. COMPANY PROFILES

8.1. Chapter Overview
8.2. 3M
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. Product Portfolio
8.2.3.1. 3M™ Hollow Microstructured Transdermal System
8.2.3.2. 3M™ Solid Microneedle
8.2.4. Recent Collaborations
8.2.5. Future Outlook
8.3. Becton Dickinson
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Product Portfolio
8.3.3.1. BD Intevia™ Handheld Autoinjector
8.3.3.2. BD Accuspray™ Nasal Spray System
8.3.4. Recent Collaborations
8.3.5. Future Outlook
8.4. Consort Medical
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. Technology Overview
8.4.4. Product Portfolio
8.4.4.1. Autoinjectors
8.4.4.1.1. Syrina
8.4.4.1.2. OTS Autoinjector
8.4.4.2. Nasal Delivery System
8.4.5. Recent Collaborations
8.4.6. Future Outlook
8.5. D’Antonio Consultants International
8.5.1. Company Overview
8.5.2. Product Portfolio
8.5.2.1. LectraJet® HS High Speed Jet Injection
8.5.2.2. LectraJet® M3 RA Needle-free Injection
8.5.2.3. Multi-Channel Jet Injector
8.5.2.4. LectraJet® M4 RA
8.6. Enesi Pharma
8.6.1. Company Overview
8.6.2. Technology Overview
8.6.3. Product Portfolio
8.6.3.1. Enesi ImplaVax®
8.6.3.2. Solid Dose Injector
8.6.4. Recent Collaborations
8.6.5. Future Outlook
8.7. Ichor Medical
8.7.1. Company Overview
8.7.2. Financial Information
8.7.3. Product Portfolio
8.7.3.1. TriGrid® Delivery System
8.7.4. Recent Collaborations
8.7.5. Future Outlook
8.8. Iconovo
8.8.1. Company Overview
8.8.2. Financial Information
8.8.3. Product Portfolio
8.8.3.1. ICOres
8.8.3.2. ICOone
8.8.3.3. ICOcap
8.8.3.4. ICOpre
8.8.4. Recent Collaborations
8.8.5. Future Outlook
8.9. Inovio Pharmaceuticals
8.9.1. Company Overview
8.9.2. Financial Information
8.9.3. Product Portfolio
8.9.3.1. ZetaJet®
8.9.3.2. Biojector® 2000
8.9.3.2. CELLECTRA® Electroporation Delivery Device
8.9.4. Recent Collaborations
8.9.5. Future Outlook
8.10. PharmaJet
8.10.1. Company Overview
8.10.2. Financial Information
8.10.3. Product Portfolio
8.10.3.1. PharmaJet Stratis® Needle-free Injector
8.10.3.2. PharmaJet Tropis® Intradermal Injection
8.10.4. Recent Collaborations
8.10.5. Future Outlook
8.11. Union Medico
8.11.1. Company Overview
8.11.2. Product Portfolio
8.11.2.1. 45° Autoinjector
8.11.2.2. 90° Autoinjector
8.11.2.3. SuperGrip Autoinjector
8.11.2.4. Exclusive Autoinjector
8.11.3. Recent Collaborations
8.11.4. Future Outlook

9. PARTNERSHIPS AND COLLABORATIONS

9.1. Chapter Overview
9.2. Partnership Models
9.3. Novel Vaccine Delivery Devices: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Type of Device
9.3.4. Analysis by Type of Partnership and Type of Device
9.3.5. Analysis by Type of Vaccine and Type of Device
9.3.6. Analysis by Type of Active Ingredient
9.3.7. Analysis by Target Disease Indication
9.3.8. Popular Vaccine Delivery Devices: Analysis by Number of Partnerships
9.3.9. Most Active Industry Players: Analysis by Number of Partnerships
9.3.10. Geographical Analysis
9.3.10.1. Intercontinental and Intracontinental Agreements

10. SWOT ANALYSIS

10.1. Chapter Overview
10.2. Strengths
10.3. Weaknesses
10.4. Opportunities
10.5. Threats
10.6. Concluding Remarks

11. MARKET SIZING AND OPPORTUNITY ANALYSIS

11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Global Novel Vaccine Delivery Devices Market, 2019-2030
11.4. Global Novel Vaccine Delivery Devices Market: Distribution by Type of Device, 2019-2030
11.5. Global Novel Vaccine Delivery Devices Market: Distribution by Route of Administration, 2019-2030
11.6. Global Novel Vaccine Delivery Devices Market: Distribution by Type of Vaccine, 2019-2030
11.7. Global Novel Vaccine Delivery Devices Market: Distribution by Regions, 2019-2030
11.7.1. Novel Vaccine Delivery Devices Market in North America, 2019-2030
11.7.1.1. Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Device, 2019-2030
11.7.1.2. Novel Vaccine Delivery Devices Market in North America: Distribution by Route of Administration, 2019-2030
11.7.1.3. Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Vaccine, 2019-2030
11.7.2. Novel Vaccine Delivery Devices Market in Europe, 2019-2030
11.7.2.1. Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Device, 2019-2030
11.7.2.2. Novel Vaccine Delivery Devices Market in Europe: Distribution by Route of Administration, 2019-2030
11.7.2.3. Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Vaccine, 2019-2030
11.7.3. Novel Vaccine Delivery Devices Market in Asia Pacific, 2019-2030
11.7.3.1. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Device, 2019-2030
11.7.3.2. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Route of Administration, 2019-2030
11.7.3.3. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Vaccine, 2019-2030
11.7.4. Novel Vaccine Delivery Devices Market in Rest of the World, 2019-2030
11.7.4.1. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Device, 2019-2030
11.7.4.2. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Route of Administration, 2019-2030
11.7.4.3. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Vaccine, 2019-2030

12. EXECUTIVE INSIGHTS

12.1. Chapter Overview
12.2. Vaxess Technologies
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Michael Schrader, Chief Executive Officer and Founder
12.3. Iconovo
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Mikael Ekstrom and Roger Lassing, Vice Presidents, Business Development
12.3. Innoture
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Henry King, Market Intelligence and Business Development Manager

13. CONCLUDING REMARKS14. APPENDIX 1: TABULATED DATA15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1 Difference between Vaccines and Small Molecules
Figure 3.2 Classification of Vaccines
Figure 3.3 Therapeutic Delivery through the Skin
Figure 3.4 Common Routes of Administration Used for Vaccines
Figure 3.5 Novel Vaccine Delivery Devices
Figure 4.1 Novel Vaccine Delivery Devices: Distribution by Type of Device
Figure 4.2 Novel Vaccine Delivery Devices: Distribution by Route of Administration
Figure 4.3 Novel Vaccine Delivery Devices: Distribution by Type of Device and Route of Administration
Figure 4.4 Novel Vaccine Delivery Devices: Distribution by Drug Delivery Mechanism
Figure 4.5 Novel Vaccine Delivery Devices: Distribution by Type of Device and Drug Delivery Mechanism
Figure 4.6 Novel Vaccine Delivery Devices: Distribution by Nature of Vaccine Administration
Figure 4.7 Novel Vaccine Delivery Devices: Distribution by Type of Device and Nature of Vaccine Administration
Figure 4.8 Novel Vaccine Delivery Devices: Distribution by Speed of Vaccine Administration
Figure 4.9 Novel Vaccine Delivery Devices: Distribution by Type of Device and Speed of Vaccine Administration
Figure 4.10 Novel Vaccine Delivery Devices: Distribution by Self-Administration Potential
Figure 4.11 Novel Vaccine Delivery Devices: Distribution by Type of Device and Self-Administration Potential
Figure 4.12 Novel Vaccine Delivery Devices: Distribution by Availability of Audio / Visual Feedback
Figure 4.13 Novel Vaccine Delivery Devices: Distribution by Type of Device and Availability of Audio / Visual Feedback
Figure 4.14 Novel Vaccine Delivery Devices: Distribution by Device Usability
Figure 4.15 Novel Vaccine Delivery Devices: Distribution by Type of Device and Device Usability
Figure 4.16 Novel Vaccine Delivery Devices: Distribution by Type of Needle
Figure 4.17 Novel Vaccine Delivery Devices: Distribution by Type of Device and Type of Needle
Figure 4.18 Novel Vaccine Delivery Devices: Distribution by Stage of Development
Figure 4.19 Novel Vaccine Delivery Devices: Distribution by Type of Device and Stage of Development
Figure 4.20 Novel Vaccine Delivery Device Developers: Distribution by Type of Developer
Figure 4.21 Novel Vaccine Delivery Device Developers: Distribution by Year of Establishment
Figure 4.22 Novel Vaccine Delivery Device Developers: Distribution by Company Size
Figure 4.23 Novel Vaccine Delivery Device Developers: Distribution by Geographical Location
Figure 5.1 Device Competitiveness Analysis: Novel Vaccine Delivery Devices
Figure 6.1 Technology Effectiveness of Devices for Marketed Vaccines: Analysis by Type of Active Ingredient
Figure 6.2 Technology Effectiveness of Devices for Marketed Vaccines: Analysis by Dosage Form
Figure 6.3 Technology Effectiveness of Devices for Marketed Vaccines: Analysis by Route of Administration
Figure 6.4 Technology Effectiveness of Devices for Marketed Vaccines: Analysis by Target Disease Indication
Figure 6.5 Technology Effectiveness of Devices for Marketed Vaccines: Analysis by Target Patient Population
Figure 6.6 Technology Effectiveness of Devices for Clinical-Stage Vaccines: Analysis by Type of Active Ingredient
Figure 6.7 Technology Effectiveness of Devices for Clinical-Stage Vaccines: Analysis by Dosage Form
Figure 6.8 Technology Effectiveness of Devices for Clinical-Stage Vaccines: Analysis by Route of Administration
Figure 6.9 Technology Effectiveness of Devices for Clinical-Stage Vaccines: Analysis by Target Disease Indication
Figure 6.10 Technology Effectiveness of Devices for Clinical-Stage Vaccines: Analysis by Target Patient Population
Figure 8.1 3M: Annual Revenues, 2015-Q2 2019 (USD Billion)
Figure 8.2 3M™ Hollow Microstructured Transdermal System: Approval Process
Figure 8.3 3M™ Hollow Microstructured Transdermal System: Advantages
Figure 8.4 3M™ Solid Microneedle: Features
Figure 8.5 Becton Dickinson: Annual Revenues, 2014-Q3 2019 (USD Billion)
Figure 8.6 Consort Medical: Annual Revenues, 2015-Q2 2019 (USD Million)
Figure 8.7 Consort Medical: Syrina® Autoinjectors
Figure 8.8 LectraJet® Technology and Devices
Figure 8.9 LectraJet® HS High Speed Jet Injection: Features
Figure 8.10 ImplaVax® Technology: Components
Figure 8.11 ImplaVax®: Features
Figure 8.12 Ichor Medical Systems: Annual Revenues, 2014-2018 (USD Million)
Figure 8.13 Ichor Medical Systems: Electroporation Process
Figure 8.14 Iconovo: Dry Powder Inhalers
Figure 8.15 Inovio Pharmaceutical: Annual Revenues, 2014-Q3 2019 (USD Million)
Figure 8.16 dMAb™ Technology: Advantages
Figure 8.17 PhrmaJet Tropis® Intradermal Injection: Administration Steps
Figure 8.18 Union Medico: Types of 45°Autoinjector
Figure 8.19 Union Medico: Components of 45°/R Autoinjector
Figure 8.20 Union Medico: Types of 90° Autoinjectors
Figure 8.21 Union Medico: Components of Exclusive Autoinjector
Figure 9.1 Partnerships and Collaborations: Cumulative Distribution by Year, 2014-2019
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Type of Device
Figure 9.4 Partnerships and Collaborations: Distribution by Year and Type of Device
Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Device
Figure 9.6 Partnerships and Collaborations: Distribution by Type of Vaccine and Type of Device
Figure 9.7 Partnerships and Collaborations: Distribution by Type of Active Ingredient
Figure 9.8 Partnerships and Collaborations: Distribution by Target Disease Indication
Figure 9.9 Partnerships and Collaborations: Popular Vaccine Delivery Devices
Figure 9.10 Partnerships and Collaborations: Most Active Players
Figure 9.11 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 10.1 Novel Vaccine Delivery Devices: SWOT Analysis
Figure 10.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 11.1. Global Novel Vaccine Delivery Devices Market, 2019-2030 (USD Million)
Figure 11.2 Global Novel Vaccine Delivery Devices Market: Distribution by Type of Device, 2019-2030 (USD Million)
Figure 11.3 Global Novel Vaccine Delivery Devices Market: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 11.4 Global Novel Vaccine Delivery Devices Market: Distribution by Type of Vaccine, 2019-2030 (USD Million)
Figure 11.5 Global Novel Vaccine Delivery Devices Market: Distribution by Regions, 2019-2030 (USD Billion)
Figure 11.6 Novel Vaccine Delivery Devices Market in North America, 2019-2030 (USD Million)
Figure 11.7 Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Device, 2019-2030 (USD Million)
Figure 11.8 Novel Vaccine Delivery Devices Market in North America: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 11.9 Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Vaccine, 2019-2030 (USD Million)
Figure 11.10 Novel Vaccine Delivery Devices Market in Europe, 2019-2030 (USD Million)
Figure 11.11 Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Device, 2019-2030 (USD Million)
Figure 11.12 Novel Vaccine Delivery Devices Market in Europe: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 11.13 Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Vaccine, 2019-2030 (USD Million)
Figure 11.14 Novel Vaccine Delivery Devices Market in Asia Pacific, 2019-2030 (USD Million)
Figure 11.15 Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Device, 2019-2030 (USD Million)
Figure 11.16 Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 11.17 Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Vaccine, 2019-2030 (USD Million)
Figure 11.18 Novel Vaccine Delivery Devices Market in Rest of the World, 2019-2030 (USD Million)
Figure 11.19 Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Device, 2019-2030 (USD Million)
Figure 11.20 Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 11.21 Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Vaccine, 2019-2030 (USD Million)

List of Tables

Table 3.1 . Classification of Vaccines
Table 3.2 . Live Attenuated Vaccines: Commonly Reported Adverse Events
Table 3.3 . Inactivated Vaccines: Commonly Reported Adverse Events
Table 3.4 . Subunit Vaccines: Commonly Reported Adverse Events
Table 3.5 . Toxoid Vaccines: Commonly Reported Adverse Events
Table 3.6 . Vaccine Excipients and Associated Functions
Table 3.7 . Routes of Administration and Delivery Devices for Vaccines
Table 3.8 . Common Pediatric Vaccines and Affiliated Routes of Administration
Table 4.1. List of Marketed Vaccines
Table 4.2. List of Clinical-Stage Vaccines
Table 4.3. Novel Vaccine Delivery Devices: List of Available / Under Development Products
Table 4.4. Novel Vaccine Delivery Devices: List of Developers
Table 7.1 . Marketed Vaccines: Likely Candidates for Delivery via Novel Vaccine Delivery Devices
Table 7.2. Marketed Vaccines: Most Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
Table 7.3. Marketed Vaccines: Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
Table 7.4 . Marketed Vaccines: Less Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
Table 7.5 . Marketed Vaccines: Least Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
Table 7.6. Marketed Vaccines: Most Likely Candidates for Delivery via Jet Injectors
Table 7.7. Marketed Vaccines: Likely Candidates for Delivery via Jet Injectors
Table 7.8 . Marketed Vaccines: Less Likely Candidates for Delivery via Jet Injectors
Table 7.9 . Marketed Vaccines: Least Likely Candidates for Delivery via Jet Injectors
Table 7.10. Marketed Vaccines: Most Likely Candidates for Delivery via Microneedle Patches
Table 7.11. Marketed Vaccines: Likely Candidates for Delivery via Microneedle Patches
Table 7.12 . Marketed Vaccines: Less Likely Candidates for Delivery via Microneedle Patches
Table 7.13 . Marketed Vaccines: Least Likely Candidates for Delivery via Microneedle Patches
Table 7.14. Marketed Vaccines: Most Likely Candidates for Delivery via Nasal Delivery Systems
Table 7.15. Marketed Vaccines: Likely Candidates for Delivery via Nasal Delivery Systems
Table 7.16 . Marketed Vaccines: Less Likely Candidates for Delivery via Nasal Delivery Systems
Table 7.17 . Marketed Vaccines: Least Likely Candidates for Delivery via Nasal Delivery Systems
Table 7.18. Marketed Vaccines: Most Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
Table 7.19. Marketed Vaccines: Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
Table 7.20 . Marketed Vaccines: Less Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
Table 7.21 . Marketed Vaccines: Least Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
Table 7.22. Marketed Vaccines: Most Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
Table 7.23. Marketed Vaccines: Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
Table 7.24 . Marketed Vaccines: Less Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
Table 7.25 . Marketed Vaccines: Least Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
Table 7.26. Marketed Vaccines: Most Likely Candidates for Delivery via Prefilled Syringes
Table 7.27. Marketed Vaccines: Likely Candidates for Delivery via Prefilled Syringes
Table 7.28 . Marketed Vaccines: Less Likely Candidates for Delivery via Prefilled Syringes
Table 7.29 . Marketed Vaccines: Least Likely Candidates for Delivery via Prefilled Syringes
Table 7.30. Clinical-Stage Vaccines: Likely Candidates for Delivery via Novel Vaccine Delivery Devices
Table 7.31. Clinical-Stage Vaccines: Most Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
Table 7.32. Clinical-Stage Vaccines: Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
Table 7.33. Clinical-Stage Vaccines: Less Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
Table 7.34 . Clinical-Stage Vaccines: Least Likely Candidates for Delivery via Electroporation-based Needle Free Injection Systems
Table 7.35. Clinical-Stage Vaccines: Most Likely Candidates for Delivery via Jet Injectors
Table 7.36. Clinical-Stage Vaccines: Likely Candidates for Delivery via Jet Injectors
Table 7.37. Clinical-Stage Vaccines: Less Likely Candidates for Delivery via Jet Injectors
Table 7.38 . Clinical-Stage Vaccines: Least Likely Candidates for Delivery via Jet Injectors
Table 7.39. Clinical-Stage Vaccines: Most Likely Candidates for Delivery via Microneedle Patches
Table 7.40. Clinical-Stage Vaccines: Likely Candidates for Delivery via Microneedle Patches
Table 7.41 . Clinical-Stage Vaccines: Less Likely Candidates for Delivery via Microneedle Patches
Table 7.42 . Clinical-Stage Vaccines: Least Likely Candidates for Delivery via Microneedle Patches
Table 7.43. Clinical-Stage Vaccines: Most Likely Candidates for Delivery via Nasal Delivery Systems
Table 7.44. Clinical-Stage Vaccines: Likely Candidates for Delivery via Nasal Delivery Systems
Table 7.45. Clinical-Stage Vaccines: Less Likely Candidates for Delivery via Nasal Delivery Systems
Table 7.46 . Clinical-Stage Vaccines: Least Likely Candidates for Delivery via Nasal Delivery Systems
Table 7.47. Clinical-Stage Vaccines: Most Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
Table 7.48. Clinical-Stage Vaccines: Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
Table 7.49 . Clinical-Stage Vaccines: Less Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
Table 7.50 . Clinical-Stage Vaccines: Least Likely Candidates for Delivery via Oral Delivery Systems for Liquid Formulations
Table 7.51. Clinical-Stage Vaccines: Most Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
Table 7.52. Clinical-Stage Vaccines: Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
Table 7.53 . Clinical-Stage Vaccines: Less Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
Table 7.54 . Clinical-Stage Vaccines: Least Likely Candidates for Delivery via Oral Delivery Systems for Solid Formulations
Table 7.55. Clinical-Stage Vaccines: Most Likely Candidates for Delivery via Prefilled Syringes
Table 7.56. Clinical-Stage Vaccines: Likely Candidates for Delivery via Prefilled Syringes
Table 7.57 . Clinical-Stage Vaccines: Less Likely Candidates for Delivery via Prefilled Syringes
Table 7.58 . Clinical-Stage Vaccines: Least Likely Candidates for Delivery via Prefilled Syringes
Table 8.1 . Novel Vaccine Delivery Devices: List of Companies Profiled
Table 8.2 . 3M: Recent Collaborations
Table 8.3 . 3M: Future Outlook
Table 8.4 . Becton Dickinson: Vaccine Delivery Devices Portfolio
Table 8.5 . Becton Dickinson: Recent Collaborations
Table 8.6 . Becton Dickinson: Future Outlook
Table 8.7 . Consort Medical: Recent Collaborations
Table 8.8 . Consort Medical: Future Outlook
Table 8.9 . Enesi Pharma: Recent Collaborations
Table 8.10 . Enesi Pharma: Future Outlook
Table 8.11 . Ichor Medical Systems: Recent Collaborations
Table 8.12 . Ichor Medical Systems: Future Outlook
Table 8.13 . Iconovo: Recent Collaborations
Table 8.14 . Iconovo: Future Outlook
Table 8.15 . Inovio Pharmaceuticals: Recent Collaborations
Table 8.16 . Inovio Pharmaceuticals: Future Outlook
Table 8.17 . PharmaJet: Recent Collaborations
Table 8.18 . PharmaJet: Future Outlook
Table 8.19 . Union Medico: Comparison of 45° Autoinjectors
Table 8.20 . Union Medico: Comparison of 90° Autoinjectors
Table 9.1 . Novel Vaccine Delivery Devices: Partnerships and Collaborations, 2014-2019 (till September)
Table 12.1 . Vaxess Technologies: Company Snapshot
Table 12.2 . Iconovo: Company Snapshot
Table 12.3 . Innoture: Company Snapshot
Table 13.1 . Novel Vaccine Delivery Devices: Summary of the Competitive Insights
Table 14.1. Novel Vaccine Delivery Devices: Distribution by Type of Device
Table 14.2. Novel Vaccine Delivery Devices: Distribution by Route of Administration
Table 14.3. Novel Vaccine Delivery Devices: Distribution by Type of Device and Route of Administration
Table 14.4. Novel Vaccine Delivery Devices: Distribution by Drug Delivery Mechanism
Table 14.5. Novel Vaccine Delivery Devices: Distribution by Type of Device and Drug Delivery Mechanism
Table 14.6. Novel Vaccine Delivery Devices: Distribution by Nature of Vaccine Administration
Table 14.7. Novel Vaccine Delivery Devices: Distribution by Type of Device and Nature of Vaccine Administration
Table 14.8. Novel Vaccine Delivery Devices: Distribution by Speed of Vaccine Administration
Table 14.9. Novel Vaccine Delivery Devices: Distribution by Type of Device and Speed of Vaccine Administration
Table 14.10. Novel Vaccine Delivery Devices: Distribution by Self-Administration Potential
Table 14.11. Novel Vaccine Delivery Devices: Distribution by Type of Device and Self-Administration Potential
Table 14.12. Novel Vaccine Delivery Devices: Distribution by Availability of Audio / Visual Feedback
Table 14.13. Novel Vaccine Delivery Devices: Distribution by Type of Device and Availability of Audio / Visual Feedback
Table 14.14. Novel Vaccine Delivery Devices: Distribution by Device Usability
Table 14.15. Novel Vaccine Delivery Devices: Distribution by Type of Device and Device Usability
Table 14.16. Novel Vaccine Delivery Devices: Distribution by Type of Needle
Table 14.17. Novel Vaccine Delivery Devices: Distribution by Type of Device and Type of Needle
Table 14.18. Novel Vaccine Delivery Devices: Distribution by Stage of Development
Table 14.19. Novel Vaccine Delivery Devices: Distribution by Type of Device and Stage of Development
Table 14.20. Novel Vaccine Delivery Device Developers: Distribution by Type of Developer
Table 14.21. Novel Vaccine Delivery Device Developers: Distribution by Year of Establishment
Table 14.22. Novel Vaccine Delivery Device Developers: Distribution by Company Size
Table 14.23. Novel Vaccine Delivery Device Developers: Distribution by Geographical Location
Table 14.24. Technology Effectiveness of Devices for Marketed Vaccines: Analysis by Type of Active Ingredient
Table 14.25. Technology Effectiveness of Devices for Marketed Vaccines: Analysis by Dosage Form
Table 14.26. Technology Effectiveness of Devices for Marketed Vaccines: Analysis by Route of Administration
Table 14.27. Technology Effectiveness of Devices for Marketed Vaccines: Analysis by Target Disease Indication
Table 14.28. Technology Effectiveness of Devices for Marketed Vaccines: Analysis by Target Patient Population
Table 14.29. Technology Effectiveness of Devices for Clinical-Stage Vaccines: Analysis by Type of Active Ingredient
Table 14.30. Technology Effectiveness of Devices for Clinical-Stage Vaccines: Analysis by Dosage Form
Table 14.31. Technology Effectiveness of Devices for Clinical-Stage Vaccines: Analysis by Route of Administration
Table 14.32. Technology Effectiveness of Devices for Clinical-Stage Vaccines: Analysis by Target Disease Indication
Table 14.33. Technology Effectiveness of Devices for Clinical-Stage Vaccines: Analysis by Target Patient Population
Table 14.34. 3M: Annual Revenues, 2015-Q2 2019 (USD Billion)
Table 14.35. Becton Dickinson: Annual Revenues, 2014-Q3 2019 (USD Billion)
Table 14.36. Consort Medical: Annual Revenues, 2015-Q2 2019 (USD Million)
Table 14.37. Ichor Medical Systems: Annual Revenues, 2014-2018 (USD Million)
Table 14.38. Inovio Pharmaceutical: Annual Revenues, 2014-Q3 2019 (USD Million)
Table 14.39. Partnerships and Collaborations: Cumulative Distribution by Year, 2014-2019
Table 14.40. Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.41. Partnerships and Collaborations: Distribution by Type of Device
Table 14.42. Partnerships and Collaborations: Distribution by Year and Type of Device
Table 14.43. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Device
Table 14.44. Partnerships and Collaborations: Distribution by Type of Vaccine and Type of Device
Table 14.45. Partnerships and Collaborations: Distribution by Type of Active Ingredient
Table 14.46. Partnerships and Collaborations: Distribution by Target Disease Indication
Table 14.47. Partnerships and Collaborations: Popular Vaccine Delivery Devices
Table 14.48. Partnerships and Collaborations: Most Active Players
Table 14.49. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 14.50. Global Novel Vaccine Delivery Devices Market, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.51. Global Novel Vaccine Delivery Devices Market: Distribution by Type of Device, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.52. Global Novel Vaccine Delivery Devices Market: Distribution by Route of Administration, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.53. Global Novel Vaccine Delivery Devices Market: Distribution by Type of Vaccine, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.54. Global Novel Vaccine Delivery Devices Market: Distribution by Regions, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.55. Novel Vaccine Delivery Devices Market in North America, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.56. Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Device, 2019-2030 (USD Million)
Table 14.57. Novel Vaccine Delivery Devices Market in North America: Distribution by Route of Administration, 2019-2030 (USD Million)
Table 14.58. Novel Vaccine Delivery Devices Market in North America: Distribution by Type of Vaccine, 2019-2030 (USD Million)
Table 14.59. Novel Vaccine Delivery Devices Market in Europe, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.60. Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Device, 2019-2030 (USD Million)
Table 14.61. Novel Vaccine Delivery Devices Market in Europe: Distribution by Route of Administration, 2019-2030 (USD Million)
Table 14.62. Novel Vaccine Delivery Devices Market in Europe: Distribution by Type of Vaccine, 2019-2030 (USD Million)
Table 14.63. Novel Vaccine Delivery Devices Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.64. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Device, 2019-2030 (USD Million)
Table 14.65. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Route of Administration, 2019-2030 (USD Million)
Table 14.66. Novel Vaccine Delivery Devices Market in Asia Pacific: Distribution by Type of Vaccine, 2019-2030 (USD Million)
Table 14.67. Novel Vaccine Delivery Devices Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 14.68. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Device, 2019-2030 (USD Million)
Table 14.69. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Route of Administration, 2019-2030 (USD Million)
Table 14.70. Novel Vaccine Delivery Devices Market in Rest of the World: Distribution by Type of Vaccine, 2019-2030 (USD Million)

Note: Product cover images may vary from those shown

3M
Abbott
AbCellera
ABO Pharmaceuticals
AC Immune
Accelovance
AdminMed
Aduro Biotech
Advagene Biopharma
Advaxis
Aelix Therapeutics
Aeras
Aesica Pharmaceuticals
Affinivax
Affiris
Agenus
AgResearch
Aimmune Therapeutics
Aivita Biomedical
AJ Vaccines
Aktiv-Dry
Alopexx Vaccine
AlphaVax
Altimmune
American Association for Cancer Research
Anhui Zhifei Longcom Biologic Pharmacy
Animal Health Board
Antares Pharma
Apogee Technology
Araclon Biotech
Archivel Farma
Argos Therapeutics
Astellas Pharma
AstraZeneca
Australian Respiratory and Sleep Medicine Institute
AVIR Green Hills Biotechnology
Axon Neuroscience
Barr Labs
Battelle
Bavarian Nordic
Baylor College of Medicine
BCN Peptides
Becton Dickinson
Beijing Center for Disease Control and Prevention
Beijing Institute of Biological Products
Beijing Minhai Biotechnology
Beijing Tricision Biotherapeutics
Beijing Wantai Biological Pharmacy Enterprise
Beijing Zhifei Lvzhu Biopharmaceutical
Bernhard Nocht Institute for Tropical Medicine
Bharat Biotech International
Bill and Melinda Gates Foundation
Bilthoven Biologicals
Biofabri
Bioject Medical Technologies
Biological E
Bio-Manguinhos
Biomedical Advanced Research and Development Authority
Biomedizinische Forschungs
BioNTech
BiondVax Pharmaceuticals
Bioneedle Technologies Group
Biontech
BioSerenTach
Birla Institute of Technology and Science
Boehringer Ingelheim
Boryung Pharmaceutical
BrightPath Biotherapeutics
Bristol-Myers Squibb
Bul Bio-National Center of Infectious and Parasitic Diseases
Cadila Health Care
Cancer Insight
Cancer Research UK
Cancer Vaccines Charitable Trust
CanSino Biologics
Capital Medical University
Celerion
Celgene
Celldex Therapeutics
Centers for Disease Control and Prevention
Center for Genetic Engineering and Biotechnology
Center for HIV/AIDS Vaccine Immunology (CHAVI)
Changhai Hospital
Charite University
Chengdu Institute of Biological Products
Children's Hospital of Philadelphia
Chinese PLA General Hospital
Chiron Behring Vaccines
Chumakov Federal Scientific Center for Research & Development of Immune-And Biological Products
City of Hope Medical Center
College of Medicine and Allied Health Sciences
Consort Medical
Corium
CosMED Pharmaceutical
Cromos Pharma
CSL
CureVac
Curevo
DALI Medical Devices
Dana-Farber Cancer Institute
D'Antonio Consultants International
Dartmouth-Hitchcock Medical Center
Debiotech
Department of Health and Human Services
Duke University
Dutch Cancer Society
Dynavax Technologies
E Ink Holdings
E3D Elcam Drug Delivery Devices
Earle A. Chiles Research Institute
Elios Therapeutics
Emergent BioSolutions
Emergent Product Development
EMMES
Emory University
Enesi Pharma
EuBiologics
Federal State Budgetary Scientific Institution
FFF Enterprises
FHI 360
FIT Biotech
Flextronics International
Flinders University
FluGen
Forschungszentrum Jülich
Fourth Military Medical University
Fred Hutchinson Cancer Research Center
Fuda Cancer Hospital
FUJIFILM Pharmaceuticals
Gamaleya Research Institute of Epidemiology and Microbiology
GC Pharma
Genentech
GeneOne Life Science
Genetic Immunity
Genexine
Genocea Biosciences
Georgia Institute of Technology
GeoVax
German Cancer Research Center
Gilead Sciences
GlaxoSmithKline
GlobeImmune
GPO-MBP
Gradalis
Grameen Foundation
Green Cross
GreenSignal Bio Pharma
Gritstone Oncology
Guangdong 999 Brain Hospital
Guangzhou Anjie Biomedical Technology
Guangzhou Trinomab Biotech
Gynecologic Oncology Group
H. Lee Moffitt Cancer Center and Research Institute
Hadassah Medical Organization
Haffkine Bio Pharmaceutical
Hemispherx Biopharma
HIV Vaccine Trials Network
Hookipa Biotech
Hoosier Cancer Research Network
Hualan Biological Bacterin
Ichor Medical Systems
Iconovo
IDRI
Il-Yang Pharmaceutical
Immatics
Immune Biosolutions
Immune Design
Immunitor
ImmunoCellular Therapeutics
Immunomic Therapeutics
ImmuPatch
Imperial College London
Imugene
INCYTO
Infectious Disease Research Institute
Innoture Medical Technology
Inovio Pharmaceuticals
Inserm
Institut Pasteur
Institute of Clinical Research
Institute of Vaccines and Medical Biologicals
International Centre for Diarrheal Disease Research
International Vaccine Institute
Intravacc
Invectys
IPPOX Foundation
ISA Pharmaceuticals
Istari Oncology
Janssen Biotech
Japan BCG Laboratory
Jiangsu Jindike Biotechnology
Jiangsu Province Centers for Disease Control and Prevention
Jinan University Guangzhou
JN-International Medical
Johns Hopkins Bloomberg School of Public Health
Jonsson Comprehensive Cancer Center
Jurong Centers for Disease Control and Prevention
Kenya Medical Research Institute
Korean Center for Disease Control and Prevention
Kurve Technology
Laboratory Corporation of America
Leiden University Medical Center
Leidos
LG Chem
Likang Life Sciences
LimmaTech Biologics
London School of Hygiene and Tropical Medicine
Louisiana State University Health Sciences Center in New Orleans
LTS
Ludwig Institute for Cancer Research
Ludwig-Maximilians-University, Charite University
LuMind Research Down Syndrome Foundation
Madison Vaccines
Mahidol University
Marker Therapeutics
Massachusetts General Hospital
MassBiologics
Mayo Clinic
MCM Vaccine
McMaster University
MD Anderson Cancer Center
Medicago
Medical International Technologies
Medical Research Council
Medical University Innsbruck
Medical University of Vienna
Medigen Vaccine Biologics
MedImmune
MEDRx
MedsForAll
Memorial Sloan Kettering Cancer Center
Mercia Pharma
Merck
Microdermics
Micron Biomedical
Micropoint Technologies
MIKROGEN
Military Infectious Diseases Research Program
Minervax
Ministry of Health of the Russian Federation
Ministry of Health and Sanitation of Sierra Leone
Moffitt Clinical Research Network
Mogam Biotechnology Research Institute
Moore Medical
MSD Wellcome Trust Hilleman Laboratories
Mundipharma
Mylan
NanoPass Technologies
NantKwest
National Cancer Institute
National Institute for Health Research
National Institute for Medical Research
National Institute of Allergy and Infectious Diseases
National Institute of Biomedical Imaging and Bioengineering
National Institute on Aging
National Institutes of Health
National Pediatric Cancer Foundation
National University Hospital
Naval Medical Research Center
Nemaura Pharma
Nemera
Neon Therapeutics
Norwegian Institute of Public Health
Nova Immunotherapeutics
Nova Laboratories
Novartis
Novavax
NovInject
Nuance Designs
OncBioMune Pharmaceuticals
OncoPep
OncoTherapy Science
Oncovir
Olymvax Biopharmaceuticals
OptiNose
Organon Teknika
Osaka University
Ospedale San Raffaele
Oswaldo Cruz Foundation
Panacea
Parexel
PATH
PepTcell
Pfizer
PharmaJet
PHC Injection Device Technologies
Philipps University Marburg Medical Center
Philips Medisize
Picofluidics
Plumbline Life Sciences
Profectus BioSciences
Prometheon Pharma
PROSENEX Ambulatoriumbetriebs
Proswell Medical
Protein Sciences
Providence Cancer Center
Providence Health & Services
PT Bio Farma
Public Health England (PHE)
Queen's University Belfast
Research Foundation for Microbial Diseases of Osaka University
Rising Tide Foundation
Robbins Instruments
Robert Koch Institut
Romagnolo Scientific Institute for the Study and Treatment of Tumors
Roswell Park Cancer Institute
Royal Liverpool and Broadgreen University Hospitals NHS Trust
Russian Academy of Sciences
Sanaria
Sanofi
Scandinavian Biopharma
Sellas Life Sciences Group
Sementis
Seqirus
Serum Institute of India
Shanghai Bovax Biotechnology
Shanghai Houchao Biotechnology
Shantha Biotechnics
Shenzhen Geno-Immune Medical Institute
Shin Nippon Biomedical Laboratories
SHL Group
Sidney Kimmel Comprehensive Cancer Center
Sinovac Biotech
SK Bioscience
Skinject
Stand Up To Cancer
Stanford University
Statens Serum Institut
Stevanato Group
Swiss Group for Clinical Cancer Research
Takeda
Task Foundation
Teva Pharmaceutical
Texas Children's Hospital
The Aurum Institute
The Clatterbridge Cancer Center
The First Affiliated Hospital of Guangdong Pharmaceutical University
The Immunobiological Technology Institute
The Methodist Hospital System
The Wistar Institute
Themis Bioscience
TheraJect
Third Military Medical University
Transgene
Treos Bio
Trudell Medical International
TuBerculosis Vaccine Initiative
UbiVac
Union Medico
United States Agency for International Development
United States Army Medical Research Institute of Infectious Diseases
United States Department of Defense
University Health Network
University Hospital Tuebingen
University Medical Center Hamburg-Eppendorf
University Medical Center Groningen
University of Arkansas
University of California
University of Cape Town Lung Institute
University of Cologne
University of Copenhagen
University of Florida
University of Groningen
University of Iowa
University of Lausanne Hospitals
University of Liverpool
University of Maryland
University of Michigan
University of Oxford
University of Pennsylvania
University of Pisa
University of Pittsburgh
University of South Australia
University of Southampton
University of Sydney
University of Washington
University of Wisconsin
University of Zaragoza
US Army Medical Research and Material Command
Vaccibody
Vaccitech
Valeritas
Valneva
Vaxart
Vaxess Technologies
VAXIMM
Vaxine
Vaxxas
VBI Vaccines
Vetter Pharma
ViciniVax
ViroStatics
Walter Reed Army Institute of Research
Washington University School of Medicine
Weill Medical College of Cornell University
West Pharmaceuticals
World Health Organization
World Vision of Ireland
Wyeth Pharmaceuticals
XEME Biopharma
Xiamen Innovax Biotech
Xiamen University
Ypsomed
Zosano Pharma

Note: Product cover images may vary from those shown

LOADING...

FEATURED COMPANIES

FEATURED COMPANIES

RELATED TAGS

RELATED PRODUCTS

Global Vaccine Delivery Devices Market 2021-2026

Vaccine Delivery Devices Market Growth Analysis and Insights, 2021: Trends, Market Size, Share Outlook and Opportunities by Type, Application, End Users, Countries and Companies to 2028

Vaccine Delivery Device Market Size Outlook to 2028 - Growth Opportunities, Vaccine Delivery Device Market Insights, Companies, Market share by Types, Applications, and Countries

Novel Vaccine Delivery Systems Market by Delivery Mode, Device: Global Opportunity Analysis and Industry Forecast, 2021-2030

Microneedles for Drug and Vaccine Delivery and Patient Monitoring. Edition No. 1